Neutralizing antibodies targeting PD-1 receptor of lymphocytes, its ligand PD-L1, and the cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) “unleash” the tumor-specific T-cell response [150] (Figure 3). This evidence concerns the gene CD274 and neoplasm.